PDCD1 and neoplasm: In addition, there are studies showing that antiangiogenic combined anti-PD-1/PD-L1 therapy can change the tumor microenvironment from immunosuppressive to immunosupportive, thus stimulating the immune response and enhancing the efficacy of immunotherapy.[33,34]